VPHOP

Nearly four million osteoporotic bone fractures cost the European health system more than 30 billion Euro per year. This figure could double by 2050. After the first fracture, the chances of having another one increase by 86%. We need to prevent osteoporotic fractures. The first step is an accurate prediction of the patient-specific risk of fracture that considers not only the skeletal determinants but also the neuromuscular condition.

The aim of VPHOP is to develop a multiscale modelling technology based on conventional diagnostic imaging methods that makes it possible, in a clinical setting, to predict for each patient the strength of his/her bones, how this strength is likely to change over time, and the probability that the he/she will overload his/her bones during daily life. With these three predictions, the evaluation of the absolute risk of bone fracture will be much more accurate than any prediction based on external and indirect determinants, as it is current clinical practice.

These predictions will be used to:

  • improve the diagnostic accuracy of the current clinical standards;
  • to provide the basis for an evidence-based prognosis with respect to the natural evolution of the disease, to pharmacological treatments, and/or to preventive interventional treatments aimed to selectively strengthen particularly weak regions of the skeleton.

For patients at high risk of fracture, and for which the pharmacological treatment appears insufficient, the VPHOP system will also assist the interventional radiologist in planning the augmentation procedure. The various modelling technologies developed during the project will be validated not only in vitro, on animal models, or against retrospective clinical outcomes, but will also be assessed in term of clinical impact and safety on small cohorts of patients enrolled at four different clinical institutions, providing the factual basis for effective clinical and industrial exploitations.

For further information, please visit:
http://www.vphop.eu

Project co-ordinator:
Istituto Ortopedico Rizzoli

Partners:

  • SCS SRL
  • Société d’Etudes et de Recherches de l’Ecole Nationale Supérieure d’Arts et Métiers
  • Universität Bern
  • Biospace Med SA
  • University of Bedfordshire
  • Technische Universiteit Eindhoven
  • Philips Medical Systems Nederland BV
  • empirica Gesellschaft für Kommunikations- und Technologieforschung mbH
  • Université de Genève (UNIGE)
  • Sylvia Lawry Centre for Multiple Sclerosis Research e.V.
  • ANSYS France SAS
  • Háskóli Íslands
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
  • Uppsala universitet
  • Charité - Universitätsmedizin Berlin
  • Eidgenössische Technische Hochschule Zürich (ETHZ)
  • BrainLAB AG
  • Katholieke Universiteit Leuven

Timetable: from 08/2008 – to 08/2012

Total cost: € 12.073.349

EC funding: € 8.989.363

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)

Related news articles::

Most Popular Now

Merck and Tencent Announce Collaboration…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public...

Merck Granted U.S. Patent for Novel Comb…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO). The patent relates...

The European Health Catapult Program for…

Through dedicated sessions, a group of international top-level investors, key healthcare leaders and industry stakeholders work closely together challenging 40+ ambitious startups to optimize their business plan and strengthen their...

Applications Now Open for Pioneering Dig…

The Yorkshire & Humber AHSN (Academic Health Science Network), in partnership with mHabitat, announces that applications for the 2019 Propel@YH digital health accelerator programme are now open. Propel@YH has been...

Flagship Axe the Fax Trust Rolls out Hyb…

Leeds Teaching Hospitals NHS Trust (LTHT), the organisation at the forefront of the national Axe the Fax campaign, is implementing an electronic fax solution to tackle its last remaining machines...

First EU Citizens Using ePrescriptions i…

The first EU patients can use digital prescriptions issued by their home doctor when visiting a pharmacy in another EU country: Finnish patients are now able to go to a...

Boehringer Ingelheim (Canada) Ltd. and I…

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology...

Final Report: Provision of a Market Stud…

The aim of the study is to examine the telemedicine market in Europe and to understand the factors that determine its development. The analysis maps telemedicine applications and solutions, and...

Open Access Drug Development Tools Featu…

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new IMI2 Call for proposals launched today. The total budget of...

The NHS Long Term Plan: Cracking the Da …

Opinion Article by Prof. Michael Thick, Chief Medical Officer, Chief Clinical Information Officer, IMS MAXIMS Reading the NHS Long Term Plan this week, I had a definite sense of déjà vu...

Big Data Approach Shown to be Effective …

Researchers at Rensselaer Polytechnic Institute who developed a blood test to help diagnose autism spectrum disorder have now successfully applied their distinctive big data-based approach to evaluating possible treatments. The...

Highland Marketing Advisory Board Respon…

The first meeting of Highland Marketing's newly expanded advisory board discussed the NHS Long Term Plan and what will be needed to make it a success. Structural change, leadership, investment...